World Library  
Flag as Inappropriate
Email this Article

Dexanabinol

Article Id: WHEBN0024011265
Reproduction Date:

Title: Dexanabinol  
Author: World Heritage Encyclopedia
Language: English
Subject: Glycine, NMDA receptor antagonists, Haim Aviv, CP 55,244, 4-HTMPIPO
Collection: Alcohols, Benzochromenes, Cannabinoids, Hu Cannabinoids, Nmda Receptor Antagonists, Phenols
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Dexanabinol

Dexanabinol
Systematic (IUPAC) name
(6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol
Identifiers
CAS Registry Number  YesY
ATC code None
PubChem CID:
ChemSpider  N
UNII  YesY
Chemical data
Formula C25H38O3
Molecular mass 386.567 g/mol
 N   

Dexanabinol (HU-211 or ETS2101[1]) is a synthetic cannabinoid derivative in development by e-Therapeutics plc. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210.[2] Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead has NMDA antagonist effects.[3] It therefore does not produce cannabis-like effects, but is anticonvulsant and neuroprotective, and is widely used in scientific research as well as currently being studied for applications such as treating head injury, stroke, or cancer.[4][5][6] It was shown to be safe in clinical trials[7] and is currently undergoing Phase I trials for the treatment of brain cancer[8] and advanced solid tumors.[9]

Contents

  • Clinical Trials 1
  • Legal status 2
    • United States 2.1
      • Florida 2.1.1
  • References 3

Clinical Trials

Dexanabinol has been studied in IV administration and oral dosing.[10] e-Therapeutics is evaluating the compound in clinical trials for brain and solid cancers.[11] Phase II studies are planned based on the results of the current trials.

A phase 1b study for hepatocellular carcinoma and pancreatic cancer was started in 2015.[12]

Legal status

United States

HU-211 is not scheduled at the federal level in the United States.[13]

Florida

"HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol)" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[14]

References

  1. ^ e-therapeutics Clinical Development Pipeline
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^ University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.
  9. ^
  10. ^
  11. ^
  12. ^
  13. ^ 21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.
  14. ^ Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.